Sarilumab
- TRADE NAME: Kevzara (Sanofi)
- INDICATIONS: Rheumatoid arthritis
- CLASS: Anti-interleukin-6 receptor monoclonal antibody, Covid-19 putative drug, Monoclonal antibody
- HALF-LIFE: 8–10 days (concentration-dependent)
FDA APPROVAL DATE: 05/22/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Live vaccines
PREGNANCY CATEGORY: N/A
Based on animal data, may cause fetal harm
Investigated for treating COVID-19.
RISK OF SERIOUS INFECTIONS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric